Kilitch Drugs (India) Limited Board Meets for Q2 FY27 Results

Kilitch Drugs (India) Limited will consider its unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, at a board meeting on November 6, with the September 2025 quarter providing a consolidated revenue base of ₹48.92 crore and profit of ₹8.04 crore.

What will Kilitch Drugs consider at its November 6 board meeting?

Kilitch Drugs will consider and approve unaudited standalone and consolidated financial results for the July-September 2026 quarter and the half-year ended September 30, 2026. The company disclosed the board-meeting schedule on November 2, 2026. The meeting is relevant because it will provide the first reported financial update for the September quarter of FY27.

The results will cover the company’s performance after the June 2026 quarter, when consolidated revenue stood at ₹44.88 crore and net profit was ₹1.96 crore. Revenue was 4.0% higher than a year earlier in Q1 FY27, while net profit was 13.0% lower, according to the reported quarterly snapshot.

The September quarter will also include half-year numbers for April to September 2026. The company has stated that both standalone and consolidated results will be placed before the board. No verified revenue or profit estimate for Q2 FY27 is available in the information provided, so the board-meeting notice should not be treated as an indication of the eventual financial outcome.

What is the reported financial base for the September quarter?

Kilitch Drugs enters the September 2026 reporting period against consolidated Q2 FY26 revenue of ₹48.92 crore and net profit of ₹8.04 crore. Its standalone net sales in the September 2025 quarter were ₹37.81 crore, down 16.62% year on year, while consolidated net sales rose 3.05% year on year to ₹48.92 crore.

The company’s consolidated quarterly sales increased from ₹43.14 crore in June 2025 to ₹48.92 crore in September 2025 and ₹53.81 crore in December 2025. Sales then rose sharply to ₹89.60 crore in March 2026 before declining to ₹44.88 crore in June 2026. This sequence shows that the March quarter was substantially stronger than the immediately preceding and following quarters.

Profitability also moved sharply across recent quarters. Consolidated operating profit was ₹5.04 crore in September 2025, ₹6.15 crore in December 2025, ₹22.14 crore in March 2026 and ₹2.94 crore in June 2026. The operating margin was reported at 6.5% in the June 2026 quarter, compared with 23.6% in March 2026 in the quarterly data provided.

How did Kilitch Drugs perform in recent reported quarters?

Kilitch Drugs reported consolidated revenue of ₹89.60 crore in the March 2026 quarter, up 46.35% year on year, while standalone net sales were ₹71.97 crore, up 27.82% year on year. The March quarter was the strongest revenue quarter in the recent series supplied and was accompanied by consolidated operating profit of ₹22.14 crore.

The subsequent June 2026 quarter showed a lower revenue run-rate at ₹44.88 crore, down 49.9% from the March quarter but 4.0% above the year-earlier period. Net profit was ₹1.96 crore, compared with ₹2.25 crore in the June 2025 quarter, resulting in the reported 13.0% year-on-year decline.

For investors, the Q2 FY27 release will provide an updated view of whether the June-quarter moderation persisted or changed during July to September. The reported figures will also allow comparison with the ₹48.92 crore consolidated revenue and ₹8.04 crore profit recorded in the September 2025 base quarter. Until the company releases the results, no conclusion can be drawn on the direction of quarterly sales or margins.

Which recent corporate actions are relevant to investors?

Kilitch Drugs held its 34th annual general meeting on August 27, 2026, where shareholders approved the FY26 audited financial statements, re-elected Mukund Mehta and ratified cost auditor fees. The meeting was held through video conferencing, according to the company update.

Separately, the board approved the sale of KEB for USD 14 million and an INR 57 crore debt conversion on October 22, 2026. The supplied disclosure also referred to the appointment of two independent directors. The available information does not state the timing of completion or the financial treatment of these actions in the September-quarter results.

The company had also announced the closure of its insider-trading compliance window from October 1, 2026 until 48 hours after release of the unaudited September-quarter results. This is a standard compliance step around the publication of unpublished price-sensitive financial information.

Why does the Q2 FY27 result matter for Kilitch Drugs investors?

The Q2 FY27 result matters because it will show the company’s revenue, profit and operating-margin trend after a wide variation in performance between March and June 2026. Consolidated revenue moved from ₹89.60 crore in March to ₹44.88 crore in June, while operating profit declined from ₹22.14 crore to ₹2.94 crore over the same period.

The September 2025 comparison is also demanding on profit, as Q2 FY26 net profit was ₹8.04 crore despite revenue of ₹48.92 crore. Investors can compare the reported Q2 FY27 numbers with this base, as well as assess the half-year performance alongside the June-quarter result already available.

The results may also provide formal disclosures relevant to the October corporate approvals, if any such disclosures are made by the company. However, the board-meeting notice only confirms consideration of financial results and does not specify any further transaction-related announcement.

Conclusion

Kilitch Drugs is scheduled to consider its Q2 FY27 and first-half FY27 unaudited standalone and consolidated results on November 6, 2026. The release follows a June quarter with ₹44.88 crore of consolidated revenue and ₹1.96 crore of profit, after an unusually strong March quarter that recorded ₹89.60 crore of revenue and ₹22.14 crore of operating profit.

Investors should watch the company’s reported September-quarter revenue, net profit and operating margin against the Q2 FY26 base of ₹48.92 crore in revenue and ₹8.04 crore in profit. They should also monitor any updates the company provides on the USD 14 million KEB sale and the INR 57 crore debt conversion approved in October.